HDL serum levels are significantly lower in patients with COPD than in never-smokers

Authors:

Abstract
Introduction: Several studies claim that patients with chronic obstructive pulmonary disease have increased HDL cholesterol (HDL) serum levels. A protective effect of increased HDL has been suggested for cardiovascular disease (CVD) – but CVD is found more frequently in COPD. Retrospective data from our hospital had shown lower HDL levels in COPD patients. Aims and Objectives: To prospectively assess HDL serum levels of COPD subjects (COPD) in comparison to smokers (S), never-smokers (NS) and subjects with Asthma-COPD-Overlap-Syndrome (ACOS). Methods: Fasting HDL serum levels were measured in COPD (FEV1/FVC 1/FVC 200 and 1 50.3%) than in 54 NS (mean: 56.3 years, 61.1% female, FEV1 98.3%) (mean ± SEM 58.22 mg/dl ± 2.11 vs. 66.1 ± 2.47; p1 96.6%) and 18 ACOS (mean: 65.4 years, 38.9% female, 47.7 py, FEV1 49.8%) (mean ± SEM 58.22 mg/dl ± 2.11 vs. 59.72 ± 2.59 vs. 59.22 ± 2.76) or between S and NS. There was a trend towards higher HDL levels in 30 steroid-treated as compared to 20 steroid-naïve COPD (mean ± SEM 60.93 mg/dl ± 2.77 vs. 54.15 ± 3.14). Conclusions: HDL serum levels were significantly lower in COPD subjects than in never-smokers. This might partially explain the increased cardiovascular risk COPD patients face.